Ngalaba Mba Nile

Na Eprel 21, 2026, Center for Drug Evaluation (CDE) nke National Medical Products Administration kwupụtara na HS-20093 maka ịgba ọgwụ (risvutatug rezetecan) ka a họpụtara dị ka onye ga-enweta Breakthrough Therapy maka ọgwụgwọ nke ndị ọrịa nwere ọrịa prostate na-eguzogide castration...GỤKWUO»

N'oge na-adịbeghị anya, Center for Drug Evaluation (CDE) nke National Medical Products Administration (NMPA) nke China kwupụtara na a kwadoro Encorafenib nwa oge maka nyocha mbụ. A ga-eji ya na cetuximab na usoro ọgwụgwọ FOLFOX dị ka ọgwụgwọ mbụ maka...GỤKWUO»

Mgbe okwu bụ́ "ọrịa kansa pancreas" pụtara na akụkọ nchọpụta—karịsịa mgbe e tinyere ya na "ọrịa imeju 25"—ọtụtụ ezinụlọ abanyela n'ọnọdụ enweghị olileanya. Ọrịa a, nke a maara dị ka "eze nke kansa," nke a chọpụtara na ọ nwere ọtụtụ ọrịa kansa, na-abụkarị...GỤKWUO»

N'oge na-adịbeghị anya, Bayer kwupụtara na National Medical Products Administration (NMPA) nke China akwadola ọgwụ ọhụrụ a na-elekwasị anya na ya bụ sevabertinib maka ọgwụgwọ ndị okenye nwere ọrịa kansa akpa ume nke na-abụghị obere mkpụrụ ndụ (NSCLC) nke a na-apụghị ịgbanahụ ma ọ bụ nke na-adịghị ahụkebe nke nwere ọrịa kansa akpa ume nke na-abụghị obere mkpụrụ ndụ (NSCLC) nke nwere HER2 (ERBB2) na-eme ka a na-agwọ ọrịa kansa akpa ume nke na-akpata ọrịa HER2 (ERBB2).GỤKWUO»

Ndị Ọrịa Mba Nile Dị Mma, Mgbe gị ma ọ bụ ndị ị hụrụ n'anya na-alụso ọrịa kansa ọgụ ma na-achọ ụzọ ọgwụgwọ dị nro ma dị irè karị, anyị ga-achọ ịkọwara gị teknụzụ oncology mgbanwe - Ultrasound Tissue Fragmentation Therapy. A na-etinye ọgwụgwọ a dị elu n'ọrụ nke ọma...GỤKWUO»

Mgbe ọrịa kansa na-eme ka ndụ ghara ịdị mma, nhọrọ ọgwụgwọ ọ bụla nwere mmetụta dị ukwuu maka ịdị mma na ùgwù nke ndụ ahụ. Maka ndị ọrịa meworo agadi, ndị na-enweghị ọrụ obi na akpa ume nke ọma, ndị na-enweghị ike ịnabata ịwa ahụ ma ọ bụ ọgwụ nkụchi obi, ma ọ bụ chọọ ụzọ dị nro iji lụso ọrịa ahụ ọgụ, ...GỤKWUO»

Na Machị 31, 2026, Center for Drug Evaluation of the National Medical Products Administration nke China nyere ozi na-atọ ụtọ: GFH375, nke GenFleet Therapeutics mepụtara, ka etinyere n'ọkwa dịka onye ga-achọ "Breakthrough Therapy" maka ọgwụgwọ nke ndị ọrịa nwere ọrịa pancreatic...GỤKWUO»

Maka ọtụtụ ndị agadi na-arịa ọrịa kansa na ezinụlọ ha, nchọpụta na-abịa na nkụda mmụọ. Karịsịa mgbe a na-eche "eze nke ọrịa kansa" ihu - kansa pancreas - ihe mgbu dị egwu na enweghị ike iri nri na-ewepụkarị ndị ọrịa ùgwù ha, na-eme ka ndị ha hụrụ n'anya nọrọ n'oké mwute. Iji...GỤKWUO»

Na Machị 24, 2024, Center for Drug Evaluation of the National Medical Products Administration nke China kwupụtara na a na-atụ aro ka a kpọọ ọgwụ ọhụrụ Teclistamab dị ka ọgwụgwọ ọhụrụ maka ọgwụgwọ monotherapy nke ndị okenye nwere ọrịa ndị na-alọghachi azụ ma ọ bụ ndị na-anaghị anabata ọgwụ...GỤKWUO»

N'oge na-adịbeghị anya, National Medical Products Administration (NMPA) kwadoro ihe ngosi ọhụrụ maka ọgwụ antibody-drug conjugate (ADC) Disitamab vedotin maka ọgwụgwọ nke ndị ọrịa kansa ara toro eto nwere obere ngosipụta HER2 (IHC 1+ ma ọ bụ IHC 2+/ISH-) na metastases imeju, ndị nwere...GỤKWUO»

Na Machị 10, 2026, e nyere ọgwụ ọhụrụ B7-H3-targeting antibody-drug conjugate (ADC) YL201 maka ịgba ọgwụ, nke MediLink Therapeutics mepụtara, Breakthrough Therapy Nhọpụta site na Center for Drug Evaluation of the National Medical Products Administration nke China. Ihe ngosi a họpụtara bụ...GỤKWUO»

N'oge na-adịbeghị anya, Center for Drug Evaluation (CDE) nke China National Medical Products Administration kwadoro ọgwụ mgbochi KSD-101, nke Kousai mepụtara, ka ọ banye na nnwale ahụike. Nke a abụghị naanị ọgwụ mgbochi mkpụrụ ndụ dendritic mbụ (DC vaccine) na China nke natara ngwa FDA IND...GỤKWUO»